SOCIETE DE PROMOTION PHARMACEUTIQUE DU MAGHREB S.A. Societe de Promotion Pharmaceutique du Maghreb S.A. Share Price
Equities
PRO
MA0000011660
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 923 MAD | -5.33% |
|
-5.45% | -7.70% |
| Sales 2021 | 630M 62.39M 4.98B | Sales 2022 | 705M 69.73M 5.57B | Capitalization | 1.07B 106M 8.44B |
|---|---|---|---|---|---|
| Net income 2021 | 69M 6.83M 545M | Net income 2022 | 75M 7.42M 593M | EV / Sales 2021 | 1.48 x |
| Net cash position 2021 | 205M 20.3M 1.62B | Net cash position 2022 | 56.78M 5.62M 449M | EV / Sales 2022 | 1.44 x |
| P/E ratio 2021 |
16.5
x | P/E ratio 2022 |
14.2
x | Employees | - |
| Yield 2021 |
3.51% | Yield 2022 |
3.75% | Free-Float | 5.88% |
More Fundamentals
* Assessed data
More news
More news
| 1 day | -5.33% | ||
| 1 week | -5.45% | ||
| Current month | -2.33% | ||
| 1 month | -1.81% | ||
| 3 months | -7.61% | ||
| 6 months | -7.98% | ||
| Current year | -7.70% |
1 week
923.00
975.00
1 month
921.00976.20
Current year
921.001 008.00
1 year
921.001 110.00
3 years
800.001 226.00
5 years
690.001 226.00
10 years
634.001 690.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | - | |
Said El Bouachi
DFI | Director of Finance/CFO | - | - |
Amine Alaoui
PRN | Corporate Officer/Principal | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ma’moun Araidah
CHM | Chairman | - | - |
Khalid Janahi
BRD | Director/Board Member | - | - |
Issam Maguiri
BRD | Director/Board Member | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 923 | -5.33% | 38 |
| 25/04/24 | 975 | 0.00% | 5 |
| 24/04/24 | 975 | +3.61% | 24 |
End-of-day quote Casablanca S.E., April 25, 2024
More quotes
Promopharm (Société de Promotion Pharmaceutique du Maghreb) specializes in manufacturing and marketing pharmaceutical, para-pharmaceutical, and cosmetic products. The group also offers subcontractor manufacturing services for pharmaceutical specialties for Moroccan and foreign laboratories. The group's activity is organized primarily around 2 areas:
- sales of drugs: products manufactured under its own name and under license;
- importing and sales of semi-finished products.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -7.70% | 91M | |
| +20.81% | 43.34B | |
| +20.44% | 21.96B | |
| +11.60% | 14.09B | |
| +12.97% | 13.64B | |
| +39.74% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- PRO Stock
